Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Anti-allergy, Anti-inflammatory, Non-steroidal drugs, Steroidal drugs, Anti-VEGF Agents, Others), By Disease Type (Dry eye, Allergies, Glaucoma, Uveitis, Other retinal disorders), By Dosage Form (Gels, Eye Solutions & Suspensions, Capsules and Tablets, Eye Drops, Ointments) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Market Growth Factors

Increase in the Number of People Suffering from Various Eye Diseases

The rising incidence of eye diseases is a significant driver propelling the global ophthalmic drugs market. Conditions such as diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, and dry eye disease are becoming highly prevalent.

• For instance, according to the 2025 World Health Organization (WHO), about 2.2 billion people have near or distance vision impairment every year.

This surge in eye related disorders is driving the need for advanced ophthalmic drugs, thereby contributing to market growth.

Increasing Product Launches of Novel Ophthalmic Solutions

The innovations in drug formulations are increasing patient compliance and expanding treatment options.

• For instance, the introduction of Alcon’s TRYPTYR in July 2025 in U.S. is a latest innovation for the treatment of dry eye disease. TRYPTYR is the first neuromodulator eye drop to rapidly increase natural tear production

Thus, launch of such novel formulations is expanding treatment options, which, in turn, boosts the market growth.

Market Restraint

High Cost of Advanced Biologic Therapies

High cost associated with biologic and novel ophthalmic drugs is impacting the widespread adoption and thereby restraining the market growth.

• For instance, in 2025, cost of gene therapy for retinal disorders such as Luxturna for inherited retinal dystrophy in the U.S. is approximately USD 850,000 per treatment.

These high costs limit accessibility and adoption of ophthalmic drugs.

Market Opportunity

Growing Adoption of Tele-Ophthalmology

The growing integration of telemedicine and digital health solutions in eye care is creating a significant opportunity for the ophthalmic drugs market.

• For instance, in March 2025, the American Academy of Ophthalmology (AAO) reported a 40% increase in tele-ophthalmology consultations across the U.S.

This expansion of digital and remote care services is improving patient access to treatment, thereby driving market growth.

Regional Analysis

North America dominated the ophthalmic drugs market in 2025, accounting for 43.07% market share. This dominance is attributed to strong adoption of advanced ophthalmic therapies, favorable reimbursement policies, an increase in screening programs, and active research and development initiatives by leading pharmaceutical companies such as AbbVie, Pfizer, Alcon, and others.

Asia Pacific Market Trends

Asis Pacific is emerging as a fastest-growing region with a CAGR of 10.11% from 2026-2034, owing to the rising prevalence of eye disorders, increasing geriatric population, growing healthcare expenditure, improving access to advanced ophthalmic treatments, and expanding awareness about eye care. Moreover, countries such as China and South Korea are actively developing domestic biologics, which also supports the market growth.

Source: Straits Analysis

Countries Analysis

U.s. Market Trends

The U.S. lead the global ophthalmic drugs market, primarily due to the FDA's approval of innovative treatments, rise in prevalence of eye diseases, and presence of supportive reimbursement policies.

• For instance, the approval of Encelto (revakinagene taroretcel-lwey), an allogeneic encapsulated cell-based gene therapy for adults with idiopathic macular telangiectasia type 2 (MacTel), a rare progressive eye disease. This approval, granted on March 5, 2025, underscores the FDA's commitment to advancing eye care through novel therapies.

Moreover, the presence of established market players and high per capita income also supports the growth of the ophthalmic drugs market in the U.S.

Germany Market Growth Factors

Germany ophthalmic drugs market growth is significantly driven by the nation's regulatory environment and rising prevalence of eye disorders. Additionally, ongoing research and collaborations between pharmaceutical companies and universities promote the development of novel ophthalmic therapies, further boosting market growth

• For instance, Boehringer Ingelheim International GmbH is actively collaborating with various research organizations to advance ophthalmic research.

Moreover, high medical expenditure and widespread access to novel therapies further support market growth.

China Market Trends

China's ophthalmic drugs market is experiencing significant growth, driven by an aging population and increasing prevalence of eye disorders such as cataracts and diabetic retinopathy. The government's emphasis on healthcare reform has improved access to eye care. Additionally, domestic pharmaceutical companies are expanding their research and development efforts, leading to the introduction of innovative ophthalmic treatments in the market. Thus, all aforementioned factors are collectively boosting the ophthalmic drugs market in China.

India Market Growth Factors

India's ophthalmic drugs market is experiencing significant growth, driven by government initiatives, increasing healthcare infrastructure, and rising awareness of eye health. For instance, the National Programme for Control of Blindness and Visual Impairment (NPCB&VI) has been instrumental in reducing the prevalence of avoidable blindness through screening and treatment programs. Additionally, the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM), launched in 2021, is enhancing healthcare across the country, improving access to specialized eye treatments, which, in turn, drives the ophthalmic drugs market growth in India.

Australia Market Trends

Australia's ophthalmic drugs market is driven by the Therapeutic Goods Administration's (TGA) rigorous approval process, ensuring the safety and efficacy of treatments. For instance, in July 2025, the TGA approved Talvey, a novel treatment for age-related macular degeneration, reflecting the agency's commitment to advancing eye care. Further, the Pharmaceutical Benefits Scheme (PBS) subsidizes several ophthalmic medications, enhancing patient access to essential treatments. These initiatives are driving the adoption of ophthalmic drugs, which, in turn, support the market growth.

Market Segmentation

Drug Class Insights

The Anti-VEGF agents segment dominated the market and accounted for a 33.04% revenue share in 2025. This growth is attributed to effective inhibition of vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and fluid leakage in the retina, leading to improved visual outcomes. Additionally, supportive healthcare coverage facilitates patient access to these therapies, which, in turn, drives the segment growth.

By Drug Class Market Share (%), 2025

Source: Straits Analysis

Disease Type Insights

The glaucoma segment is expected to register the fastest CAGR growth of 9.83%, owing to increasing prevalence of glaucoma worldwide, rising awareness of early diagnosis, and the growing adoption of advanced therapeutics such as prostaglandin analogs, beta-blockers, and combination therapies that effectively manage intraocular pressure and slow disease progression.

Dosage Form Insights

The eye drops segment dominated the market in 2025. This growth is attributed to their ease of administration, wide availability, and effectiveness in treating common ocular conditions such as dry eye, allergic conjunctivitis, and glaucoma. Additionally, ongoing innovations in formulation, including preservative-free and sustained-release drops, have enhanced patient compliance and therapeutic outcomes.